PhRMA Statement on State of the Union

Washington, D.C. (January 24, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani released the following statement in response to the President's State of the Union address:

APEC Mexico City Principles for Voluntary Codes of Business Ethics in the Biopharmaceutical Sector

Speech: Remarks of John J. Castellani Before the National Italian American Federation

Thank you, John, for that kind introduction. And thanks also to the National Italian American Foundation for inviting me to take part in this Series of Distinguished Lectures. To be asked to take part in an event that has featured so many Washington men and women whom I admire… It’s a true honor. And it is a pleasure to be speaking to a room full of people whose names also end in a vowel. 
 

PhRMA Statement on Preserving American Jobs, Fostering Innovation

Washington, D.C. (September 7, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani released the following statement today about American jobs:
 

PhRMA Statement on Biosimilars Regulatory Pathway

Washington, D.C. (August 4, 2011) —Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President David E. Wheadon today issued the following statement on the FDA’s ongoing efforts to develop a user fee program and regulatory pathway for biosimilars products:
 
“A perspective piece published today in The New England Journal of Medicine outlines important themes in the ongoing development of an effective and efficient review and approval process for biosimilars.
 

PhRMA Statement on President Obama’s Debt Reduction Speech

Washington, D.C. (April 13, 2011) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani today released the following statement:

"PhRMA firmly supports a viable, comprehensive policy framework to cultivate an environment that encourages innovative biopharmaceutical companies to remain and grow in the U.S. And we welcome the opportunity to work with the President and Congress to achieve this shared goal.

Highlights of John Castellani’s CNBC Squawk Box Appearance

04.11.11 By Grady Forrer

Day Two
[10:05 a.m.]

Two Women Scientists Honored with PhRMA’s 2011 Discoverers Award

New Survey Emphasizes Value of Biopharmaceutical Company Engagement With Healthcare Providers

Washington, D.C. (March 29, 2011) — Nearly eight out of 10 physicians view pharmaceutical research companies and their sales representatives as useful sources of information on prescription medicines, according to a survey released today by KRC Research.

PhRMA Statement on AARP Report

Washington, D.C. (March 28, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) Deputy Vice President Karl Uhlendorf issued the following statement:

“AARP again is ignoring the key facts about the marketplace for prescription medicines.

“Growth in spending for prescription medicines has slowed to historic lows. According to IMS Health, prescription drug spending will grow between three percent and five percent this year, and at 3.5 percent annually through 2013.

PhRMA Statement on the Earthquake in Japan

Washington, D.C. (March 16, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani today released the following statement:

Pages

Subscribe to RSS - Opinion